文摘
摘要目的:描述人口和杜克MG诊所注册病人的临床特点胸腺切除术。
背景:注册表是一个clinician-derived数据库包含全面的病人信息中看到公爵MG诊所。
设计/方法:数据从306年注册病人胸腺切除术杜克大学医学中心从1975年到2011年。所有胸腺切除术进行使用开放技术。并不是所有数据都对所有患者可用。
结果:306名患者中,163(53%)是女性,251(83%)乙酰胆碱受体抗体(AR-pos)和53例(17%)没有(AR-neg)。肌肉特定激酶(麝香)抗体存在于13 AR-neg和1 AR-pos病人;这两个抗体- 4。抗体的数据没有在2。
在发病平均年龄32±16年男性,女性和43±19和相似AR-pos(37±19年)和AR-neg(35±15年)的病人。12眼毫克(OMG)。意味着疾病持续时间AR-pos胸腺切除术是3.19年和2.37年AR-neg病人。那些广义毫克(GMG)在胸腺切除术有较短的疾病持续时间(3.0年)比OMG(4.5年)。胸腺增生的在AR-pos和AR-neg病人的40%。胸腺瘤出现在18%的病人,所有人AR-pos。意思是胸腺切除术后随访7.3年;70%的AR-neg AR-pos和60%患者达到最小或更好的表现。药物或完整的稳定的AR-pos缓解达到27%,GMG AR-neg的22%,24%和64%的OMG患者。
结论:我们回顾了数据在公爵毫克诊所注册306 MG病人胸腺切除术。胸腺增生是最常见的组织学发现不管抗体状态或疾病的分布。结果在所有子组有利。进一步的子群分析计划描述麝香MG和双血清反应阴性的MG。
披露:拉贾博士的机构已经收到了来自美国的大脑研究支持基金会/美国重症肌无力基金会临床科学家开发奖。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围作为顾问一致的卫生服务。桑德斯博士已经收到个人补偿的范围0 - 499美元为Cabaletta生物担任顾问。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围作为顾问Kashiv生物科学。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围为詹森RnD担任顾问。桑德斯博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会动量制药。桑德斯博士已经收到相关出版物的出版版税卫生保健。Guptill博士已经收到个人薪酬在500 - 4999美元的范围为Grifols担任顾问。Guptill博士已经收到个人薪酬在5000 - 9999美元的范围为Jacobus担任顾问。Guptill博士已经收到个人补偿的范围0 - 499美元为Cabaletta担任顾问。 Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BD. Dr. Guptill has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Piedmont Pharmaceuticals. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta. Dr. Guptill has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Guptill has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Guptill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Guptill has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Guptill has received research support from Momenta. The institution of Dr. Guptill has received research support from Ra Pharma. The institution of Dr. Guptill has received research support from NIH. The institution of Dr. Guptill has received research support from MGFA. The institution of Dr. Guptill has received research support from PCORI. The institution of Dr. Guptill has received research support from Elysium Health. The institution of Dr. Guptill has received research support from Verily. An immediate family member of Dr. Hobson-Webb has received personal compensation for serving as an employee of G1 Therapeutics. Dr. Hobson-Webb has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley Publishing. The institution of Dr. Hobson-Webb has received research support from Sanofi Genzyme. The institution of Dr. Juel has received research support from PCORI. The institution of Dr. Juel has received research support from Alexion. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. The institution of Dr. Massey has received research support from Revance .
